Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Anti-cancer drug assessment method

An evaluation method and technology of anti-cancer agents, which are applied in the fields of biochemical equipment and methods, tumor/cancer cells, compound screening, etc., to achieve the effect of simple implementation

Active Publication Date: 2018-12-21
TOPPAN INC
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as a method for evaluating the drug efficacy of angiogenesis inhibitor combination therapy, at present, animal models such as mice or human evaluation methods are generally used, and there are no reports of examples of evaluation in vitro (for example, see Patent Document 3, Non-Patent Document 3, and Non-Patent Document 4)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-cancer drug assessment method
  • Anti-cancer drug assessment method
  • Anti-cancer drug assessment method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0137] [Example 1] Fabrication of a cell structure having a vascular structure

[0138] Fabricate a cell structure composed of fibroblasts and vascular endothelial cells and have a vascular network structure, and observe the vascular network structure.

[0139] As the cell structure including the vascular network structure, human neonatal skin fibroblasts (manufactured by Lonza, CC-2509, Normal Human Dermal Fibroblasts: NHDF), human umbilical cord vein endothelial cells (manufactured by Lonza, CC-2509) were used. 2517A, Human Umbilical Vein Endothelial Cell: HUVEC) A cell structure formed by two types of cells. In addition, as a cell culture container, a Transwell insert cell culture device (manufactured by Corning, product number: #3470) was used, and as a medium, a 10% by volume bovine serum (manufactured by System Biosciences, EXO-FBS-50A-1) was used. D-MEM (manufactured by Wako Pure Chemical Industries, Ltd., product number: 043-30085) and 1% by volume of penicillin / strep...

Embodiment 2

[0148] The anticancer effect of the anticancer agent doxorubicin was evaluated using a cell structure composed of fibroblasts, vascular endothelial cells, and cancer cells and having a vascular network structure.

[0149] As a cell structure containing cancer cells and a vascular network structure, human neonatal skin fibroblasts (Normal Human Dermal Fibroblasts: NHDF) (Lonza, CC-2509) and human umbilical cord vein endothelial cells (Lonza , CC-2517A, HUVEC) (Lonza Corporation, CC-2517), the top surface of the cell structure formed by the two types of cells formed by the human colorectal adenocarcinoma cell line HT29 (ATCC code: HTB-38TM) Cell structure of cancer cell layer. In addition, as a cell culture vessel, a Transwell insert cell culture device (manufactured by Corning, product number: #3470) was used, and as a medium, a 10% by volume bovine serum (manufactured by Corning, product number: #35-010- CV) and D-MEM (manufactured by Wako Pure Chemical Industries, Ltd., prod...

Embodiment 3

[0169] The anticancer effect of the anticancer agent doxorubicin was evaluated using a cell structure in which the vascular network structure was formed in layers and a cell structure in which the vascular network structure was similarly dispersed throughout the structure.

[0170] The cell culture vessel, medium, and doxorubicin were the same as those used in Example 2.

[0171]

[0172] Will 2×10 6 NHDF and 3×10 4 A cell structure was constructed in the same manner as in Example 2, except that each HUVEC was suspended in Tris-HCl buffer containing heparin and collagen. The obtained cell structure is a cell structure in which a cancer cell layer is laminated on a layer in which the vascular network structure is dispersed throughout the structure (mixed layer (21 layers) of NHDF (20 layers) and HUVEC (1 layer)-HT29 (1 story)).

[0173]

[0174] First, the 1×10 6 Each NHDF was suspended in a Tris-HCl buffer containing heparin and collagen (0.1 mg / mL heparin, 0.1 mg / mL c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This anti-cancer drug assessment method involves: a culturing step for culturing a cell structure containing cells which constitute cancer cells and stromal tissue while in the presence of one or moretypes of anti-cancer drug; and an assessment step for assessing the anti-cancer effect of the anti-cancer drug, with the indicator thereof being the viable cell count of the cancer cells in the cellstructure following the culturing step.

Description

technical field [0001] The present invention relates to a method for more reliably evaluating the anticancer effect of an anticancer agent in an in vitro system without using an animal model. In addition, the present invention relates to a method for evaluating the anticancer effect of an anticancer agent in an in vitro system without using an animal model. A method for evaluating with high precision whether or not an anticancer effect higher when an angiogenesis inhibitor is used in combination with an anticancer agent is obtained than when an anticancer agent is used alone. [0002] This application is based on Japanese Patent Application No. 2016-083948 filed in Japan on April 19, 2016, Japanese Patent Application No. 2016-083950 filed in Japan on April 19, 2016, and Japanese Patent Application No. 2016-083950 filed in Japan on April 19, 2016. Priority is claimed by Japanese Patent Application No. 2016-083951, and the contents thereof are incorporated in this application. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/02
CPCG01N33/5011G01N33/5064G01N33/5047C12N5/0697C12N2502/1323C12N2502/28C12N2513/00C12N5/0693C12N2503/04G01N33/5088G01N33/5085G01N2500/10
Inventor 北野史朗塚本圭入江新司
Owner TOPPAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com